Komori
Revision of earnings forecasts4925HABA LABORATORIES,INC.Materials and Chemicals

Notice Regarding Revisions to the Numerical Targets of the Second Medium-Term Management Plan

The numerical targets in the medium-term management plan for the fiscal year ending March 2028 have been lowered. Revenue has been revised from ¥16 billion to ¥13.7 billion, and operating profit from ¥1.2 billion to ¥950 million.

Worth reading
58In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Deterioration
Direction inferred from the company’s description.
Scale
-2300
¥ million (revenue revision)
Wording
Avoiding a definitive answer
How definitive the wording is.

Revised forecast

Fiscal year ending March 2028 · Full yearPrevious forecast published 9 May 2025
Net Sales16,000→13,700million
-14.4%
Operating profit1,200→950million
-20.8%

The bar length represents the relative magnitude of change, based on the item that changed the most in this document.

Reason for the revision

Although product development progressed smoothly, gaps from the initial assumptions arose in areas including the lead time to realizing sales, planning accuracy, the acquisition of new customers, and the response to inbound demand, while the domestic and overseas business environments also evolved differently from the assumptions underlying the plan. The initial plan, which prioritized business expansion, will be shifted to a stable-growth model focused on profitability and efficiency.

Previous-period resultsRevenue: ¥12,141 million; operating profit: ¥727 million (fiscal 2025, fiscal year ended March 2026)
Consolidated / non-consolidatedConsolidated
Revised forecast
ItemDetails
Net Sales¥16,000 million → ¥13,700 million(-14.4%)
Operating profit¥1,200 million → ¥950 million(-20.8%)
Fiscal Period CoveredFiscal year ending March 2028
Period CoveredFull year
Publication date of previous forecast9 May 2025
Previous-period resultsRevenue: ¥12,141 million; operating profit: ¥727 million (fiscal 2025, fiscal year ended March 2026)
Reason for the revisionAlthough product development progressed smoothly, gaps from the initial assumptions arose in areas including the lead time to realizing sales, planning accuracy, the acquisition of new customers, and the response to inbound demand, while the domestic and overseas business environments also evolved differently from the assumptions underlying the plan. The initial plan, which prioritized business expansion, will be shifted to a stable-growth model focused on profitability and efficiency.
Consolidated / non-consolidatedConsolidated
Items this document does not state (5)
Ordinary incomeProfit attributable to owners of the parentNet income per shareDetails and amount of extraordinary lossDividend forecast revision

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Although product development progressed smoothly, there were gaps from the initial assumptions in the lead time to realizing sales, planning accuracy, the acquisition of new customers, and the response to inbound demand. In addition, the domestic and overseas business environments evolved differently from the assumptions underlying the plan, making more cautious business management necessary. Accordingly, the Company has shifted from a plan prioritizing business expansion to a stable-growth model focused on profitability and efficiency.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Revisions to the Numerical Targets of the Second Medium-Term Management Plan | HABA LABORATORIES,INC. (4925) timely disclosure | Komori